001     896717
005     20220103172033.0
024 7 _ |a 10.3390/molecules26051294
|2 doi
024 7 _ |a 1420-3049
|2 ISSN
024 7 _ |a 2128/29098
|2 Handle
024 7 _ |a 33673611
|2 pmid
024 7 _ |a WOS:000628431800001
|2 WOS
037 _ _ |a FZJ-2021-03550
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Berning, Lena
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment
260 _ _ |a Basel
|c 2021
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1637661268_26757
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various bacteria, exerts different biological activities including the modulation of these two cellular stress response pathways. We analyzed the effect of prodigiosin on protein levels of different autophagy- and apoptosis-related proteins in cisplatin-sensitive and -resistant urothelial carcinoma cells (UCCs). Furthermore, we investigated the effect on cell viability of prodigiosin alone or in combination with cisplatin. We made use of four different pairs of cisplatin-sensitive and -resistant UCCs. We found that prodigiosin blocked autophagy in UCCs and re-sensitized cisplatin-resistant cells to apoptotic cell death. Furthermore, we found that prodigiosin is a potent anticancer agent with nanomolar IC50 values in all tested UCCs. In combination studies, we observed that prodigiosin sensitized both cisplatin-sensitive and -resistant urothelial carcinoma cell lines to cisplatin treatment with synergistic effects in most tested cell lines. These effects of prodigiosin are at least partially mediated by altering lysosomal function, since we detected reduced activities of cathepsin B and L. We propose that prodigiosin is a promising candidate for the therapy of cisplatin-resistant urothelial carcinomas, either as a single agent or in combinatory therapeutic approaches
536 _ _ |a 2171 - Biological and environmental resources for sustainable use (POF4-217)
|0 G:(DE-HGF)POF4-2171
|c POF4-217
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Schlütermann, David
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Friedrich, Annabelle
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Berleth, Niklas
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Sun, Yadong
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Wu, Wenxian
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Mendiburo, María José
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Deitersen, Jana
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Brass, Hannah
|0 P:(DE-Juel1)169140
|b 8
|u fzj
700 1 _ |a Skowron, Margaretha A.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Hoffmann, Michèle J.
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Niegisch, Günter
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Pietruszka, Jörg
|0 P:(DE-Juel1)128906
|b 12
|u fzj
700 1 _ |a Stork, Björn
|0 P:(DE-HGF)0
|b 13
|e Corresponding author
773 _ _ |a 10.3390/molecules26051294
|g Vol. 26, no. 5, p. 1294 -
|0 PERI:(DE-600)2008644-1
|n 5
|p 1294 -
|t Molecules
|v 26
|y 2021
|x 1420-3049
856 4 _ |u https://juser.fz-juelich.de/record/896717/files/molecules-26-01294-v2.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:896717
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)169140
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 8
|6 P:(DE-Juel1)169140
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 9
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 11
|6 P:(DE-HGF)0
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 12
|6 P:(DE-Juel1)128906
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 12
|6 P:(DE-Juel1)128906
910 1 _ |a Heinrich-Heine-Universität Düsseldorf
|0 I:(DE-HGF)0
|b 13
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Forschungsbereich Erde und Umwelt
|l Erde im Wandel – Unsere Zukunft nachhaltig gestalten
|1 G:(DE-HGF)POF4-210
|0 G:(DE-HGF)POF4-217
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-200
|4 G:(DE-HGF)POF
|v Für eine nachhaltige Bio-Ökonomie – von Ressourcen zu Produkten
|9 G:(DE-HGF)POF4-2171
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-05-04
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOLECULES : 2019
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-05-04
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-05-04
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-05-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-05-04
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)IBOC-20090406
|k IBOC
|l Institut für Bioorganische Chemie (HHUD)
|x 0
920 1 _ |0 I:(DE-Juel1)IBG-1-20101118
|k IBG-1
|l Biotechnologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)IBOC-20090406
980 _ _ |a I:(DE-Juel1)IBG-1-20101118
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21